PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2012; 12: 306.
Published online Jul 23, 2012. doi:  10.1186/1471-2407-12-306
PMCID: PMC3414782
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
Catharina Medrek,corresponding author1 Fredrik Pontén,2 Karin Jirström,3 and Karin Leandersson1
1Center for Molecular Pathology, Jan Waldenströmsgata 59, Skåne University Hospital, Lund University, 20502, Malmö, Sweden
2Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden
3Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, 221 85, Lund, Sweden
corresponding authorCorresponding author.
Catharina Medrek: catharina.medrek/at/med.lu.se; Fredrik Pontén: fredrik.ponten/at/igp.uu.se; Karin Jirström: karin.jirstrom/at/med.lu.se; Karin Leandersson: karin.leandersson/at/med.lu.se
Received February 11, 2012; Accepted July 23, 2012.
Abstract
Background
Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer.
Methods
The extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival.
Results
We found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival.
Conclusion
These findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.
Keywords: Tumor associated macrophages, Tumor stroma, CD163, CD68
Articles from BMC Cancer are provided here courtesy of
BioMed Central